Register for our free email digests:
Division of Osteologix Holdings PLC
Latest From Ariad Pharmaceuticals Inc.
Former directors of pharmacovigilance and risk management agree to pay disgorgements and civil penalties in SEC complaints charging them with trading in Ariad stock in advance of FDA announcements about the leukemia drug Iclusig.
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
CEO Christophe Weber remains resolutely upbeat on the progress of Takeda's strategic transformation plan, the dividends of which he said are apparent in the leading Japanese pharma firm's fiscal year performance.
The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Osteologix Inc.
- Western Europe
- Parent & Subsidiaries
- Osteologix Holdings PLC
- Senior Management
Philip J Young, CEO
Baxter Phillips, III, Senior. Dir., Corporate Dev.
- Contact Info
Phone: (45) 39179730
Symbion Science Park
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.